Finding Maximum Tolerated Dose in Phase I Oncology Clinical Trials with Bayesian Methods

被引：0
|
作者：
Sapi, Johanna [1 ,2 ]
机构：
[1] Obuda Univ, Biomat & Appl Artificial Intelligence Inst, John von Neumann Fac Informat, Becsi Ut 96-B, H-1034 Budapest, Hungary
[2] Obuda Univ, Univ Res & Innovat Ctr, Physiol Controls Res Ctr, Becsi Ut 96-B, H-1034 Budapest, Hungary
来源：
ACTA POLYTECHNICA HUNGARICA | 2024年 / 21卷 / 06期
关键词：
maximum tolerated dose (MTD); dose-limiting toxicity (DLT); Continual Reassessment Method (CRM); Time-To-Event Continual Reassessment Method (TITE- CRM); copula regression model; logistic regression model; delayed toxicities; late-onset toxicity model; CONTINUAL REASSESSMENT; DESIGN; TOXICITY; COMBINATIONS; AGENT;
D O I：
暂无
中图分类号：
T [工业技术];
学科分类号：
08 ;
摘要：
Maximum tolerated dose (MTD) is a maximal amount of drug or radiation resulting relatively acceptable dose-limiting toxicity (DLT). Accurate value of MTD should be found in Phase I trials in order to create the possibility to conduct successful Phase II (pilot efficacy and safety evaluation) and Phase III (comparative efficacy) trials. The aim of this paper is to review the difficulties of the dose-finding methods including multi-agent problems and late-onset toxicities, and to discuss Bayesian adaptive dose-finding methods which can handle these issues.
引用
收藏
页码：129 / 145
页数：17
相关论文
共 50 条
  • [21] Maximum tolerated dose estimations using various stopping rules in phase I clinical trial
    Jeon, Soyoung
    Kim, Dongjae
    KOREAN JOURNAL OF APPLIED STATISTICS, 2022, 35 (02) : 251 - 263
  • [22] A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation
    Abbas, Rachid
    Rossoni, Caroline
    Jaki, Thomas
    Paoletti, Xavier
    Mozgunov, Pavel
    CLINICAL TRIALS, 2020, 17 (05) : 522 - 534
  • [23] DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
    Ursino, Moreno
    Biard, Lucie
    Chevret, Sylvie
    BIOMETRICAL JOURNAL, 2022, 64 (08) : 1486 - 1497
  • [24] Uniformly most powerful Bayesian interval design for phase I dose-finding trials
    Lin, Ruitao
    Yin, Guosheng
    PHARMACEUTICAL STATISTICS, 2018, 17 (06) : 710 - 724
  • [25] Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity
    Thall, PF
    Lee, SJ
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (03) : 251 - 261
  • [26] The Expected Toxicity Rate at the Maximum Tolerated Dose in the Standard Phase I Cancer Clinical Trial Design
    Seung-Ho Kang
    Chul Ahn
    Drug information journal : DIJ / Drug Information Association, 2001, 35 : 1189 - 1199
  • [27] The expected toxicity rate at the maximum tolerated dose in the standard Phase I cancer clinical trial design
    Kang, SH
    Ahn, C
    DRUG INFORMATION JOURNAL, 2001, 35 (04): : 1189 - 1199
  • [28] Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
    Beibei Guo
    Yisheng Li
    BMC Medical Research Methodology, 14
  • [29] Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
    Guo, Beibei
    Li, Yisheng
    BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
  • [30] BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS
    Yuan, By Ying
    Yin, Guosheng
    ANNALS OF APPLIED STATISTICS, 2011, 5 (2A) : 924 - 942
12345